Compare GXO Logistics Inc (GXO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GXO Logistics Inc vs Viatris Inc — how do they compare? GXO Logistics Inc trades at $53.9 (market cap $6.22B), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Viatris Inc is far larger — about 3.3× GXO Logistics Inc's market cap, and Viatris Inc pays a 2.73% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals.
| GXO | VTRS | |
|---|---|---|
Market Cap | $6.22B | $20.50B |
Sector | Industrials | Health |
52-Week High | $65.59 | $17.59 |
52-Week Low | $45.52 | $8.74 |
Enterprise Value | $11.39B | $32.71B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GXO Logistics trades at $52.80, down 2.31% today but maintains strong analyst support with 16 buy ratings and an $66.60 consensus price target representing 26% upside potential. The company has beaten earnings estimates for three consecutive quarters, with Q1 2026 EPS of $0.50 surpassing expectations by 35%. Technical indicators show a bullish trend with support at $52 and resistance at $54, while fundamentals reveal solid revenue growth from $13.18B to $13.5B projected for 2026.
GXO presents a compelling growth opportunity with expanding partnerships and improved profitability, though investors should monitor competitive pressures in the logistics sector and the company's ability to maintain earnings momentum. The stock's current valuation at 47x P/E appears elevated but is supported by strong analyst conviction and consistent operational execution.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GXO Logistics Inc
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
